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I
n patients suffering from clinically relevant atherosclerotic disease of femoropopliteal arteries, the iteration of self-expanding nitinol stents has reduced the technical shortcomings associated with earlier devices 1 and has expanded their use to highly complex anatomies. As a trade-off, vessel renarrowing at the stented level occurs in 30% to 40% of patients within 2 to 3 years of implantation 2 and represents a challenging clinical problem. 3 Multiple endovascular technologies have been evaluated as stand alone or combined therapies for in-stent restenosis (ISR) of femoropopliteal arteries. 4 Among others, balloon catheters coated with the taxol-derivative paclitaxel, a high lipophilic antiproliferative drug, have attracted considerable interest. 5 Drug-coated balloon angioplasty (DCB) has been associated with favorable angiographic and clinical efficacy in the treatment of de novo lesions of femoropopliteal arteries. 6 However, despite the initially promising results observed in single-arm registries, 7, 8 subsequent randomized trials of DCB versus plain balloon angioplasty for femoropopliteal ISR were inconclusive because of the lack of statistical power to properly investigate clinical outcomes, 9, 10 particularly across patients at higher risk for recurrence.
Against this background, we performed an individual patient data meta-analysis including participants with femoropopliteal ISR randomly assigned to either DCB or plain balloon angioplasty.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The material will be available on formal request at Deutsches Herzzentrum Munchen, Technische Universität Munchen, Munich, Germany.
Search Strategy and Selection Criteria
For inclusion in the current analysis, randomized trials of DCB therapy for patients with femoropopliteal ISR were identified by searching Medline, EMBASE, the CENTRAL (Cochrane Central Register of Controlled Trials), scientific sessions abstracts, and relevant websites (http://www.clinicaltrialresults.org, http:// www.escardio.org, http://www.tctmd.com, and http://www. theheart.org). No restrictions in terms of language or publication status were imposed. The references listed in all eligible studies were checked to identify further citations. Search terms included the keywords and the corresponding Medical Subject Headings for femoropopliteal (femoral) artery, in-stent restenosis, drug-coated (-eluting) balloon, trial, and randomized trial. Inclusion criteria were (1) randomized design, (2) percutaneous revascularization with DCB angioplasty because of femoropopliteal ISR, and (3) a minimum of 6-month follow-up. Exclusion criteria were (1) vessels treated with DCB angioplasty other than femoropopliteal arteries and (2) perprotocol use of endovascular devices other than DCB in the experimental group. We updated a previous search of scientific databases performed on July 2016 for articles dealing with the topic under investigation 11 and performed the final search on September 2017. The reference lists from all eligible studies were checked to identify further citations.
Collection of Patient-Level Data and Assessment of Risk of Bias
Two investigators (Drs Cassese and Massimiliano Fusaro) independently assessed publications for eligibility at title and abstract level. Divergences were resolved by consensus. Studies that met inclusion criteria were selected for further analysis. Freedom from bias was evaluated for each study in accordance with The Cochrane Collaboration method. 12 No formal quality score adjudication was performed. 13 Of a number of 4 studies identified through the electronic search, one randomized trial, 14 available as meeting presentation, was excluded because the principal investigator did not agree to share patient-level data and available information did not allow time-to-event analyses. Therefore, 3 randomized trials 9,10,15 remained for inclusion. The principal investigators of these studies were contacted to provide individual data of participants randomly assigned to DCB or plain balloon angioplasty. Data were transferred without patient identifiers to the Deutsches Herzzentrum Munchen, Technische Universität Munchen, Munich, Germany, and combined in a single pooled database. The final dataset was checked for completeness and consistency and compared with the results from prior publications. Principal investigators were directly contacted in case of inconsistencies with the original publications or requirement for additional data. Divergences were resolved by consensus. Data were analyzed according to the intention-to-treat principle. Each study included in the present analysis was approved
WHAT IS KNOWN
• Drug-coated balloon angioplasty has been associated with favorable clinical efficacy in the treatment of de novo lesions of femoropopliteal arteries. The clinical performance of drug-coated balloons in patients with femoropopliteal in-stent restenosis remains controversial.
WHAT THE STUDY ADDS
• In this pooled analysis of individual participant data from 3 randomized trials enrolling patients with femoropopliteal in-stent restenosis, drugcoated balloon angioplasty displayed superior efficacy without safety issues in comparison to plain balloon angioplasty at 1-year follow-up.
• There was no attrition of efficacy by implementing drug-coated balloon angioplasty in high-risk patients, as those with diabetes mellitus, longer or calcified underlying lesions, and smaller or completely occluded vessels.
• Future studies should confirm these results at longterm follow-up and assess the comparative clinical efficacy of different percutaneous strategies in this challenging clinical scenario.
by the institutional review board or ethics committee at each participating center, and all patients signed informed, written consent before receiving the assigned treatment.
Outcome Variables
The primary outcome of the current analysis was target lesion revascularization (TLR). The main secondary outcome was recurrent ISR. Other outcomes of interest were ipsilateral amputation, death, Rutherford class improvement, and ankle-brachial index (ABI) at follow-up. All end points were evaluated according to definitions of original protocols.
Statistical Analysis
The individual participant data meta-analysis was performed using a 1-stage approach. The intention-to-treat population was used for analysis, and events beyond 12 months were censored to preserve a homogeneous follow-up duration among trials. The total follow-up was defined as the time from index procedure until death, last follow-up date or 12 months, whichever came first. In case of >5% missing data for outcomes of interest, we performed a multivariate imputation by chained equation assuming that data was missing at random. . A Cox regression analysis was used for formal interaction testing to evaluate the consistency of treatment effects between subgroups. In addition, a landmark analysis (from 0 to 6 months and from 6 to 12 months) evaluated a possible time dependence of treatment effect for TLR.
A further analysis with a 2-stage approach was performed for TLR and recurrent ISR. The HRs and 95% CIs by each trial were derived from individual participant data and were pooled using inverse variance weighting. Summary estimates were derived by means of DerSimonian and Laird random-effects models. We measured the between-study variance using the I 2 statistic: I 2 values of <25%, 25% to 50%, or >50% were suggested to indicate low, moderate, or high heterogeneity. 12 Finally, we tested the robustness of the present metaanalysis by performing a trial sequential analysis, in which meta-analysis sample size calculations are combined with the threshold of statistical significance, as previously described by Wetterslev et al. 16 We did not evaluate the publication bias because of the small number of trials included in this study. All analyses were performed by using STATA software package, release 13 (STATA Corp, College Station, TX). This study was conducted in compliance with the Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data statement (Table I in the Data Supplement).
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RESULTS
Eligible Studies
The process of study selection is summarized in the Figure  I in the Data Supplement. A total of 3 studies comparing DCB versus plain balloon angioplasty were included, all reported as full-length articles. 9, 10, 15 The risk of bias among studies included is reported in the Table II in the Data Supplement. Finally, a total of 263 participants (133 allocated to DCB and 130 allocated to plain balloon angioplasty) with 263 treated lesions were studied.
The main characteristics of the studies included are described in the Table 1 . All trials had a multicenter, randomized design. 9, 10, 15 Main inclusion criteria in the original trials were the evidence of ISR of femoropopliteal arteries (≥70% in diameter), with symptoms ranging from claudication to ischemic ulcer. Main exclusion criteria were significant untreated inflow or outflow disease, thrombosis of target limb, or end-stage renal disease. Balloon catheters used were coated with paclitaxel (at a dose of 3 10 or 3.5 μg/mm 29,15 of balloon surface) or uncoated. The antiproliferative drug was directly delivered from the balloon surface into the vessel wall with a carrier consisting of an organic excipient (urea 9, 15 or shellac 10 ). Device descriptions are summarized in the Table III in the Data Supplement. In all studies, bailout stenting after angioplasty was allowed in case of suboptimal result after dilation in both treatment arms.
An overview of main clinical end points definitions among trials included is reported in the Table IV in the Data Supplement. In 2 trials, the primary end point consisted of the incidence of recurrent (binary) ISR at 6-or 12-month follow-up measured with duplex sonography or computed tomography. 9, 10 In the remaining trial, 15 the primary end point was the percentage diameter stenosis at invasive angiographic surveillance performed 6 to 8 months after index procedure. The clinical characteristics of participants are reported in the Table 2 and were well balanced among groups. Overall, patients had a mean age of 69 years, were predominantly males, and with a high frequency of diabetes mellitus, and nearly 40% of cases had a concomitant coronary artery disease. There was no difference between patients treated with DCB and those treated with plain balloon in terms of ABI or functional status at baseline. Overall, critical limb ischemia (Rutherford class 4-5) was reported in 11 patients (4.2%), with comparable frequencies among groups (3.0% versus 5.5%, P=0.88 for DCB versus plain balloon angioplasty).
The angiographic characteristics of participants are displayed in the Table 3 and were comparable across groups. Roughly one-third of lesions presented a class III ISR. 3 Overall, mean reference diameter was 5.23 mm (median, 5 mm; interquartile range, 5-6), mean lesion length was 124.5 mm (median, 120 mm; interquartile range, 45-187), and mean diameter stenosis was 89.5% (median, 90%; interquartile range, 80-100). A moderate to severe underlying calcification was present in nearly half of treated lesions. A total of 26 patients (9.8%) received bailout stenting, with comparable frequencies among groups. Standard medical therapy was prescribed to all patients irrespectively of the treatment received. The minimum prescription of dual antiplatelet therapy after revascularization was 3 to 6 months in all cases.
Of those included, a number of 260 patients (98.8%) were available for assessment of outcomes of interest out to 12 months: among these many, 117 patients completed a 12-month follow-up, while the mean duration of follow-up in the remaining cohort was 6.3 months. The baseline features of patients with and without a complete 12-month follow-up were broadly comparable (Tables V and VI in the Data Supplement).
Risk Estimations of Main Outcomes According to Time-to-Event Analyses
The Table 4 resumes the main outcomes of this analysis. TLR occurred in 57 patients (21.9%; Figure 1A ). The risk of TLR was significantly reduced in patients treated with DCB versus plain balloon angioplasty (13 
Risk Estimations of Main Outcomes According to Random-Effects Meta-Analysis
We found a lower risk for TLR (HR [95% CI]: 0.25 [0.14-0.46]; P<0.001; Figure 1B Figure 2B ) associated with DCB versus plain balloon angioplasty. We performed no random-effects meta-analysis for the outcome death because of the paucity of events.
Other Outcomes of Interest and Subgroup Analysis
There was no instance of ipsilateral amputation in both treatment groups. At 1 year, patients treated with DCB angioplasty presented a Rutherford class distribution comparable to that of patients treated with plain balloon angioplasty (P=0.22; Figure IIIA There was no modification of the risk estimate for TLR according to sex (P int =0.51), diabetic status (P int =0.70), lesion length (P int =0.42), vessel diameter (P int =0.61), presence of moderate to severe underlying calcification (P int =0.16), or occlusive pattern of ISR (P int =0.88; Figure 3 ).
Power Calculation
Each of the individual trials 9, 10, 15 included in this report contained only sufficient power for surrogate outcomes. In contrast, the present meta-analysis had 84% power to disclose a benefit in terms of TLR associated with DCB versus plain balloon angioplasty. Notably, the trial sequential analysis revealed that the sample size accumulated provided robust evidence for TLR ( Figure IV in the Data Supplement). Thus, even if updated with more information, the current meta-analysis would not provide additional evidence and is likely to remain the best evidence base for comparisons of DCB versus plain balloon angioplasty in patients with femoropopliteal ISR for the foreseeable future.
DISCUSSION
This meta-analysis pooled individual participant data from 3 randomized trials to study the performance of DCB in patients suffering from ISR of femoropopliteal arteries. In all trials, the control group consisted of patients treated with plain balloon angioplasty.
The main findings are that in patients suffering from ISR:
1. At 1-year follow-up, DCB has superior efficacy without safety issues in comparison to plain balloon angioplasty. 2. DCB angioplasty shows no attrition of efficacy in high-risk patients, as those with diabetes mellitus, longer or calcified underlying lesions, and smaller or completely occluded vessels. Despite the encouraging results of modestly sized randomized trials 9, 10, 15 and a meta-analysis of aggregate data,
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European guideline-writing authorities have recently assigned a weak recommendation for DCB angioplasty in patients with femoropopliteal ISR (class of recommendation IIb, level of evidence B). 18 To date completed randomized trials of DCB angioplasty for femoropopliteal ISR lack statistical power for clinical end points: this fact is likely to represent the main argument against a stronger recommendation for this therapy. In light of these considerations, we performed an individual patient data meta-analysis of randomized trials to investigate the clinical performance of DCB as compared with plain balloon angioplasty in patients with ISR of femoropopliteal arteries, with particular attention to those individuals at higher risk for recurrence. This report highlights a number of important issues.
Reduced Risk for TLR and Recurrent ISR 1 Year After DCB Angioplasty
In the present analysis, a strategy of DCB versus plain balloon angioplasty for femoropopliteal ISR was associated with a 75% relative reduction in the hazard of TLR and 81% reduction in the hazard of recurrent ISR at 1-year follow-up. Clinically driven TLR has been widely used to quantify the success of revascularization procedures though it represents a less objective discriminator of comparative device efficacy. Although recurrent ISR may not correlate with clinical symptoms, it provides a more objective measure of comparative device efficacy. 19 This study showed that in patients with femoropopliteal ISR the suppression of neointimal growth through the antiproliferative effect of DCB led to a consistent lower risk for repeat revascularization and recurrent ISR. The magnitude of treatment effect of DCB observed in this analysis is in line with previous nonrandomized investigations of femoropopliteal ISR, with comparable follow-up duration. 20, 21 In this regard, a follow-up longer than 1 year remains crucial to definitively ascertain the durability of DCB efficacy in this setting. In fact, Schmidt et al 8 have recently demonstrated a dropoff of vessel patency 2 years after DCB therapy for femoropopliteal ISR. In contrast, recent studies documented a high patency up to 2 years after DCB angioplasty in the same setting.
15,22
Reduced Risk for TLR at 1 Year in High-Risk Subgroups Treated With DCB Angioplasty
This analysis is based on the largest cohort of patients randomly allocated to DCB or plain balloon angioplasty for femoropopliteal ISR in the setting of controlled clinical trials. We found for the first time a consistent reduction of TLR at 1-year follow-up with DCB versus plain balloon angioplasty in high-risk subgroups of patients with femoropopliteal ISR, such as those with diabetes mellitus, longer or calcified underlying lesions, and smaller or completely occluded vessels. A previous study including diabetic patients with femoropopliteal ISR found that the superior clinical efficacy over plain balloon angioplasty observed with DCB at 1-and 2-year follow-up dissipated completely at 3 years. 23 Here, we found a higher efficacy at 1-year follow-up in patients with diabetes mellitus treated with DCB versus plain balloon angioplasty. However, a longer follow-up remains pivotal, 24 especially in patients with more complex lesions. Recent observations suggest that DCB angioplasty provides no meaningful benefit to patients with occlusive femoropopliteal ISR, 23, 25 regardless of followup duration. Although these results are in contrast with the present study, they were obtained from cohorts of patients smaller than those with occlusive pattern of femoropopliteal ISR available for this meta-analysis.
Future Directions in the Percutaneous Treatment of Femoropopliteal ISR
The superior efficacy of DCB as compared with plain balloon angioplasty observed in this study did not improve Rutherford classification and ABI at 1-year follow-up. This fact highlights the potential bias of classification systems based on self-reported symptoms. 19 In addition, the frequent involvement of below-the-knee vessels in patients with femoropopliteal ISR, as displayed in this study, limits reliable ABI measurements. In this regard, future studies should aim at quantifying the impact of drug-coated therapies on functional status by means of less biased and reproducible tests (eg, 6 minutes walking distance).
In this analysis, DCB platforms were coated with high paclitaxel doses (3-3.5 μg/mm 2 of balloon surface). Preclinical model of femoropopliteal ISR treated with DCB platforms loaded with lower doses of paclitaxel displayed less drug tissue levels at long-term, despite comparable degrees of neointimal inhibition. 26 The impact of these findings on clinical efficacy of DCB 27 and the role of this therapy against revascularization strategies other than plain balloons in patients with femoropopliteal ISR remain to be further studied. In addition, although the combination of different endovascular technologies for femoropopliteal ISR holds promise, 28 randomized trials powered for clinical outcomes have yet to be performed. Finally, the use of endovascular imaging (such as optical coherence tomography) for femoropopliteal ISR should be improved, to disclose in vivo the pathophysiological mechanisms underlying this condition.
2,29
Study Limitations
The current study presents a number of limitations. First, this meta-analysis has limitations inherent to pooled analyses and reflects the flaws of the original trials, especially in terms of missing outcomes data because of the relatively high rates of dropouts at follow-up. Second, the majority of participants randomly assigned to either DCB or plain balloon angioplasty complained of claudication, while only a minority presented with tissue loss. In this respect, the current results cannot be extrapolated to this subgroup of patients. Third, all randomized trials included in this meta-analysis were open label and this introduces potential bias. Fourth, the duration and type of antiplatelet therapies varied among studies, and the possible effect of a prolonged or more potent platelet inhibition cannot be disclosed in this context. Finally, included trials were not designed to evaluate the clinical efficacy of DCB versus plain balloon angioplasty in subgroups of patients with different clinical and angiographic complexity; in this regard, all analyses performed in this study are post hoc and remain exploratory in nature. In addition, although we found no significant heterogeneity in the treatment effect for main clinical outcomes, the comparative efficacy of different DCB technologies in this clinical setting has yet to be investigated.
Conclusions
This meta-analysis based on individual participant data suggests that in patients presenting ISR of femoropopliteal arteries a therapy with DCB provides superior clinical performance at 1-year follow-up as compared with plain balloon angioplasty. There is no attrition of efficacy with DCB in patients presenting femoropopliteal ISR and higher risk for recurrence. Future dedicated studies are required to confirm these results at longterm follow-up.
